Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled study
Povorcitinib demonstrated substantial total body and facial repigmentation in adult patients with extensive nonsegmental vitiligo and was generally well tolerated through 52 weeks of treatment.
Authors
- Thierry Passeron (ORCID: https://orcid.org/0000-0002-0797-6570)
- Nanja van Geel (ORCID: https://orcid.org/0000-0002-3249-8195)
- Leandro L. Santos (ORCID: https://orcid.org/0000-0001-9986-6047)
- Khaled Ezzedine (ORCID: https://orcid.org/0000-0002-5468-4589)
- Kurt Brown
- Amit G. Pandya (ORCID: https://orcid.org/0000-0002-3916-2651)
- Andrew Blauvelt (ORCID: https://orcid.org/0000-0002-2633-985X)
- Lois Erskine
- Kofi Wagya
Institutions
- Ghent University Hospital (BE)
- Maryland Department of Natural Resources (US)
- Incyte (United States) (US)
Publication Details
- Journal
- Journal of the American Academy of Dermatology
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1016/j.jaad.2025.06.027
- Citations
- 6
- Primary Topic
- melanin and skin pigmentation
- Type
- article
- Field-Weighted Citation Impact
- 6.91
Funders
- Incyte